Medmix H1 FY26 net income drops 88.3% to CHF 0.8 million; revenue falls 7.9% to CHF 214.4 million

• Medmix H1 2026 revenue fell 7.9% to CHF 214.4 million, while operating income (EBIT) dropped 32.9% to CHF 10.6 million.
• Net income slid 88.3% to CHF 0.8 million, reflecting CHF 3.8 million of restructuring costs and CHF 2.6 million of impairment charges.
• Adjusted EBITDA (non-IFRS) eased 3% to CHF 43.5 million, while the adjusted EBITDA margin widened 0.4 percentage point to 20.3%.
• Free cash flow rose 4.6% to CHF 12 million as net capex fell 44.2% to CHF 10 million.
• CEO René Willi said organizational simplification is improving speed and execution; 2026 guidance was maintained for flat to low single-digit organic revenue growth and ~20% adjusted EBITDA margin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medmix Ltd. published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.